The FDA approved tirzepatide for weight loss under the brand name Zepbound.
It has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending.
Zepbound will be available in the U.S. by the end of the year at a list price of $1,059.87 a month, according to Lilly.
That compares with a list of $1,349 per-package for Novo Nordisk's (NOVOb.CO) wildly popular weight-loss drug Wegovy.
After Wednesday's FDA approval, Lilly can now promote the drug for weight loss.
Persons:
Eli Lilly, Mike Segar, Eli Lilly's, ” John Sharretts, Lilly, Morningstar, Damien Conover, Conover, drugmaker, Robert Kushner, Mounjaro, Patrick Wingrove, Leroy Leo, Bhanvi, Shinjini Ganguli, Bill Berkrot
Organizations:
Company, REUTERS, U.S . Food, Drug Administration, U.S, FDA, FDA’s Center, Drug, Research, Novo Nordisk's, Reuters, Northwestern University Feinberg School of Medicine, Thomson
Locations:
Branchburg , New Jersey, U.S, Indianapolis, United States, New York, Bengaluru